Asarfi Hospital Q3 FY26: ₹46 Cr Quarterly Revenue, 101% PAT Surge, 21.6 P/E — Jharkhand’s Mini Apollo in the Making?
1. At a Glance – The Smallcap with Surgical Precision
₹364 crore market cap. ₹185 share price. 12.6% return in 3 months. 105% return in one year. Quarterly sales up 40%. Quarterly profit up 101%.
Ladies and gentlemen, welcome to Asarfi Hospital Ltd — the Dhanbad-based hospital that just delivered a double-century in profit growth while operating from coal country.
Q3 FY26 revenue came in at ₹46.06 crore, and PAT jumped to ₹5.48 crore. Annualised EPS (₹2.78 × 4) works out to ₹11.12. At ₹185, the stock trades at roughly 16.6x annualised earnings — while the reported trailing P/E is 21.6. Industry median P/E? 46.7.
ROCE stands at 15.8%, ROE at 14.1%, OPM at 19.5%. Debt to equity is 0.54. Promoters hold 61.2% with zero pledge.
And this isn’t some random clinic. This is a 315-bed healthcare platform with oncology, cardiac surgeries, and now — a multi-organ transplant ambition.
So the real question is: Is this Jharkhand’s quiet healthcare compounder — or just a lucky quarter?
Let’s scrub in.
2. Introduction – From Coal Belt to Cardiac Belt
When you think of Dhanbad, you think of coal mines. Not cardiac surgeries. Not radiation oncology. Not transplant units.
Yet here we are.
Asarfi Hospital started in 2005. Over two decades, it built a multi-specialty hospital in Baramuri, launched a cancer institute in Ranguni, and acquired land in Ranchi for a research institute.
That’s not ambition. That’s expansion with a blueprint.
The Super Multi-Specialty Hospital has 250 beds (target 350). The Cancer Institute has 50 beds (target 150). Vision 2027? 500 beds.
Revenue target by FY27? ₹200 crore. Peak potential at full utilisation? ₹300+ crore.
Now pause.
Current TTM sales: ₹160 crore. They want ₹200 crore in two years.
That implies serious utilisation ramp-up.
But here’s the spicy part — oncology alone contributes 54% medical oncology, 17% surgical oncology, 17% radiation oncology. Cancer is not just a department here. It’s a revenue engine.
And oncology margins are typically higher than general medicine.
Are they quietly building a specialty moat in Eastern India?
Let’s dissect.
3. Business Model – WTF Do They Even Do?
Three verticals. Simple.
1️ Super Multi-Specialty Hospital – Dhanbad
250 beds across 100,000+ sq ft. Cardiology and neurology together generate nearly 50% of revenue.
That means this isn’t a general fever-and-cough hospital. This is heart surgeries, neuro procedures, ICU billing.
